Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024
March 14, 2024 16:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., March 14, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused building...
CORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
March 11, 2024 09:57 ET
|
Dyadic International, Inc.
In a release issued under the same headline on Monday, March 11th by Dyadic International, Inc. (NASDAQ: DYAI), please note that the city in the dateline should be JUPITER, Fla. not JUNIPER, Fla. The...
Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
March 11, 2024 08:30 ET
|
Dyadic International, Inc.
JUNIPER, Fla., March 11, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Dyadic to Attend Industry Events in March
March 01, 2024 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla. , March 01, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform
February 28, 2024 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla. and BUNNIK, the Netherlands, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company...
Global IL-17 Biologics Research Report 2023-2030: A $4.37 Billion Market in 2022 - Advancements in Monoclonal Antibody Engineering Fuel Development of Targeted IL-17 Biologics
February 20, 2024 10:57 ET
|
Research and Markets
Dublin, Feb. 20, 2024 (GLOBE NEWSWIRE) -- The "Global IL-17 Biologics Market (2023 Edition): Analysis By Indication, By Drug (Secukinumab, Ixekizumab, Bimekizumab, Brodalumab), By Region, By...
Dyadic to Attend BIO CEO & Investor Conference and European Industry Events
February 01, 2024 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Industry Forecast to 2032: U.S. Projected to Maintain Dominance, Driven by Innovative Therapies Entering the Market
January 30, 2024 07:43 ET
|
Research and Markets
Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) - Market Insights, Epidemiology, and Market Forecast - 2032" report has been added to ...
Global mRNA Therapeutics Market Set to Reach $21 Billion by 2028 Despite Decline, Fueled by Next-Gen Drugs
January 25, 2024 09:54 ET
|
Research and Markets
Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "mRNA: Therapeutics and Global Markets" report has been added to ResearchAndMarkets.com's offering.The global market for mRNA therapeutics reached $60...
Next Generation Antibody Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2031
January 25, 2024 09:50 ET
|
Research and Markets
Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "Next Generation Antibody Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology,...